WGU D116 ADVANCED
PHARMACOLOGY PRE-ASSESSMENT
EXAM QUESTIONS AND ANSWERS
2026/2027
1. A patient with chronic kidney disease (CKD) requires a medication that is primarily
excreted via the renal system. How should the clinician adjust the dosing regimen based on
pharmacokinetics?
A. Increase the dose to compensate for slower excretion.
B. Decrease the dosing interval to maintain steady state.
C. Change the administration route to avoid first-pass metabolism.
D. Decrease the dose or lengthen the dosing interval.
Answer: D
Conceptual Explanation: In patients with renal impairment, the clearance of drugs
excreted by the kidneys is reduced, leading to potential toxicity. Adjustments involve
decreasing the dose or increasing the time between doses to prevent accumulation.
,2. A patient is prescribed a drug that is a known potent inducer of the CYP3A4 enzyme
system. If this patient is also taking a second drug metabolized by CYP3A4, what is the most
likely result for the second drug?
A. Increased plasma levels and potential toxicity.
B. Decreased plasma levels and reduced therapeutic effect.
C. No change in plasma levels but increased side effects.
D. Increased bioavailability due to inhibition of first-pass effect.
Answer: B
Conceptual Explanation: Inducers increase the activity of CYP450 enzymes, leading to
faster metabolism and lower plasma concentrations of substrate drugs, which often results
in therapeutic failure.
3. Which of the following describes the ‘steady state’ of a drug in the body?
A. When the rate of drug administration equals the rate of drug elimination.
B. When the drug reaches its maximum concentration (Cmax) after the first dose.
C. When the drug is completely absorbed from the GI tract.
D. When the drug is distributed equally between the plasma and the tissues.
Answer: A
, Conceptual Explanation: Steady state is achieved when the amount of drug being
absorbed/administered is equal to the amount being eliminated, typically occurring after 4
to 5 half-lives.
4. A clinician is prescribing an ACE inhibitor to a patient with heart failure. Which mechanism
of action explains the benefit of this drug class in this population?
A. Directly blocking beta-1 receptors in the myocardium.
B. Inhibiting the conversion of Angiotensin I to Angiotensin II.
C. Increasing the secretion of aldosterone from the adrenal cortex.
D. Acting as a calcium channel blocker to reduce peripheral resistance.
Answer: B
Conceptual Explanation: ACE inhibitors block the conversion of Angiotensin I to
Angiotensin II, a potent vasoconstrictor, thereby reducing afterload and preload, and
decreasing remodeling in heart failure.
5. A patient taking Warfarin is started on a course of Amiodarone. Why is this interaction
clinically significant?
A. Amiodarone is a Vitamin K agonist.
B. Amiodarone induces CYP3A4, decreasing Warfarin efficacy.
C. Amiodarone inhibits CYP2C9, increasing Warfarin levels.
D. Warfarin increases the metabolism of Amiodarone, leading to arrhythmias.
PHARMACOLOGY PRE-ASSESSMENT
EXAM QUESTIONS AND ANSWERS
2026/2027
1. A patient with chronic kidney disease (CKD) requires a medication that is primarily
excreted via the renal system. How should the clinician adjust the dosing regimen based on
pharmacokinetics?
A. Increase the dose to compensate for slower excretion.
B. Decrease the dosing interval to maintain steady state.
C. Change the administration route to avoid first-pass metabolism.
D. Decrease the dose or lengthen the dosing interval.
Answer: D
Conceptual Explanation: In patients with renal impairment, the clearance of drugs
excreted by the kidneys is reduced, leading to potential toxicity. Adjustments involve
decreasing the dose or increasing the time between doses to prevent accumulation.
,2. A patient is prescribed a drug that is a known potent inducer of the CYP3A4 enzyme
system. If this patient is also taking a second drug metabolized by CYP3A4, what is the most
likely result for the second drug?
A. Increased plasma levels and potential toxicity.
B. Decreased plasma levels and reduced therapeutic effect.
C. No change in plasma levels but increased side effects.
D. Increased bioavailability due to inhibition of first-pass effect.
Answer: B
Conceptual Explanation: Inducers increase the activity of CYP450 enzymes, leading to
faster metabolism and lower plasma concentrations of substrate drugs, which often results
in therapeutic failure.
3. Which of the following describes the ‘steady state’ of a drug in the body?
A. When the rate of drug administration equals the rate of drug elimination.
B. When the drug reaches its maximum concentration (Cmax) after the first dose.
C. When the drug is completely absorbed from the GI tract.
D. When the drug is distributed equally between the plasma and the tissues.
Answer: A
, Conceptual Explanation: Steady state is achieved when the amount of drug being
absorbed/administered is equal to the amount being eliminated, typically occurring after 4
to 5 half-lives.
4. A clinician is prescribing an ACE inhibitor to a patient with heart failure. Which mechanism
of action explains the benefit of this drug class in this population?
A. Directly blocking beta-1 receptors in the myocardium.
B. Inhibiting the conversion of Angiotensin I to Angiotensin II.
C. Increasing the secretion of aldosterone from the adrenal cortex.
D. Acting as a calcium channel blocker to reduce peripheral resistance.
Answer: B
Conceptual Explanation: ACE inhibitors block the conversion of Angiotensin I to
Angiotensin II, a potent vasoconstrictor, thereby reducing afterload and preload, and
decreasing remodeling in heart failure.
5. A patient taking Warfarin is started on a course of Amiodarone. Why is this interaction
clinically significant?
A. Amiodarone is a Vitamin K agonist.
B. Amiodarone induces CYP3A4, decreasing Warfarin efficacy.
C. Amiodarone inhibits CYP2C9, increasing Warfarin levels.
D. Warfarin increases the metabolism of Amiodarone, leading to arrhythmias.
